Home LifestyleHealth Pfizer will launch a coronavirus vaccine trial for pregnant women and recruit about 4,000 people to participate.
Pfizer will launch a coronavirus vaccine trial for pregnant women and recruit about 4,000 people to participate.

Pfizer will launch a coronavirus vaccine trial for pregnant women and recruit about 4,000 people to participate.

by YCPress

February 19 According to the report of China.com, Pfizer announced on the 18th that it will start clinical trials of the coronavirus vaccine among pregnant women.

Pfizer said it would be the first to start the clinical trial in the United States, which is the first time that the United States has included pregnant women in such trials.

Pfizer plans to recruit about 4,000 pregnant women in the United States, Argentina, Brazil, Canada, Chile, Mozambique, South Africa, Spain and the United Kingdom to participate in the trial, requiring them to be over 18 years old and 24 to 34 weeks pregnant.

In the trial, one group of pregnant women will be vaccinated against the novel coronavirus, and the other group will receive placebo.

After giving birth, they will know whether they are in the vaccine group or the placebo group, and then the placebo group pregnant women will have the opportunity to get vaccinated.

Researchers will monitor whether the vaccine has any negative impact on women, such as whether it causes abortion.

At present, they have some preliminary data, because some women are pregnant during the early trial phase of Pfizer vaccine.

“At this point, we’re not seeing any red flags in pregnant women who have been vaccinated,” said Stacey Stewart, president of the U.S. nonprofit, the Birth Defect Foundation.

But pregnant women are at higher risk of complications after contracting COVID-19, including preterm delivery and the need to use a ventilator, according to the U.S. Centers for Disease Control and Prevention (CDC).

CDC currently does not provide clear guidance on vaccination for pregnant women.

The report said that the clinical study will also follow up for six months after the birth of the newborn to see if the antibodies produced by the mother will transfer to the baby.